Doni F, Kheir A, Manfredi M, Piemonti C, Staffiere E, Todd S, Rimondini A
Reparto di Cardiologia e UTIC, Policlinico San Pietro.
Cardiologia. 1996 Feb;41(2):135-40.
Transesophageal atrial pacing is effective in the interruption of atrial flutter, and being simple and minimally invasive, is easily performed even on outpatients. The influence of antiarrhythmic drugs on this procedure is controversial. We investigated whether the administration of oral propafenone may facilitate the procedure. Thirty patients with type I atrial flutter were randomized into two groups in which transesophageal pacing was attempted, respectively, without treatment (Group A) and after oral administration of propafenone 600 mg (Group B). Transesophageal pacing was effective in interrupting atrial flutter in 53% (8/15) of patients in Group A and in 85% (13/15) of patients in Group B. A significant lengthening of the flutter cycle was observed in patients treated with propafenone (261 +/- 23 vs 217 +/- 25 ms, p < 0.01). Sinus rhythm resumed at a shorter paced cycle in patients of Group A (166 +/- 13 vs 187 +/- 14 ms, p < 0.01). The transesophageal threshold for stable atrial capture was significantly lower in Group A (20.5 +/- 0.2 vs 23.3 +/- 1.2 mA, p < 0.01). In no patient the threshold for atrial capture was higher than the pain threshold. We did not observe abrupt enhancement of atrioventricular conduction. We can conclude that propafenone is effective and safe when used with transesophageal pacing in the termination of atrial flutter. The depressing effect of the drug on intraatrial conduction and the possible stabilizing effect on the reentry circuit appear to be outweighed by the positive effect of propafenone on the excitable gap of the circuit, facilitating its capture and account for the beneficial effect of the drug on arrhythmia termination.
经食管心房起搏在终止心房扑动方面是有效的,且操作简单、微创,甚至门诊患者也易于实施。抗心律失常药物对该操作的影响存在争议。我们研究了口服普罗帕酮是否有助于该操作。30例I型心房扑动患者被随机分为两组,分别在未治疗(A组)和口服600mg普罗帕酮后(B组)尝试经食管起搏。经食管起搏在A组53%(8/15)的患者和B组85%(13/15)的患者中有效终止了心房扑动。在接受普罗帕酮治疗的患者中观察到扑动周期显著延长(261±23 vs 217±25ms,p<0.01)。A组患者在较短的起搏周期恢复窦性心律(166±13 vs 187±14ms,p<0.01)。A组稳定心房夺获的经食管阈值显著更低(20.5±0.2 vs 23.3±1.2mA,p<0.01)。在任何患者中,心房夺获阈值均未高于疼痛阈值。我们未观察到房室传导突然增强。我们可以得出结论,普罗帕酮与经食管起搏联合用于终止心房扑动时是有效且安全的。该药物对心房内传导的抑制作用以及对折返环路可能的稳定作用,似乎被普罗帕酮对环路可兴奋间隙的积极作用所抵消,从而促进其夺获,并解释了该药物对心律失常终止的有益作用。